Highly rated in
Highly rated in
Check Dr. Bruce R. Korf's experience treating your condition:
About Dr. Bruce R. Korf

Bruce Korf is a Pediatrics specialist and a Medical Genetics expert in Birmingham, Alabama. Korf has been practicing medicine for over 43 years and is highly rated in 11 conditions, according to our data. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), RASopathies, and Legius Syndrome. He is licensed to treat patients in Alabama. Korf is currently accepting new patients.

His clinical research consists of co-authoring 138 peer reviewed articles and participating in 9 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Bruce R. Korf it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Bruce R. Korf accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter

Call to see if your plan is accepted.
720 20th St S, Kaul Human Genetics Building Room 230, Birmingham, AL 35233
Other Locations
2000 6th Ave S, Floor 1, Birmingham, AL 35233
1600 7th Ave S, Birmingham, AL 35233
Background & Education
Graduate Institution
Js Weill Medical College, Cornell University, 1980
Medical Genetics
Clinical Genetics in AL
Hospital Affiliations
UAB Hospital
USA Health University Hospital
Childrens Of Alabama
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
View 6 Less Clinical Trials -

138 Total Publications

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors